Abstract Search

ea0049ep1015 | Pituitary - Clinical | ECE2017

Osilodrostat maintains normalized urinary free cortisol levels in a majority of patients with Cushing’s disease: Long-term results from an extension to the LINC-2 study

Young Jacques , Hatipogulu Betul , Molitch Mark E , Bertagna Xavier , Barbier Nathalie , Sauter Nicholas , Biller Beverly M K , Pivonello Rosario

Background: In the 22-week LINC-2 study, osilodrostat (LCI699), a potent oral 11β-hydroxylase inhibitor, normalized urinary free cortisol (UFC) levels in 15 of 19 patients with Cushings disease (CD). The most common AEs were nausea, diarrhea, asthenia, and adrenal insufficiency (n=6 each). Here, we report the 31-month efficacy and safety results from LINC-2 extension.Methods: Patients receiving clinical benefit at week 22 could enter ...

2 shares

Endocrine Abstracts

Osilodrostat maintains normalized urinary free cortisol levels in a majority of patients with Cushing’s disease: Long-term results from an extension to the LINC-2 study

BiosciAbstracts